[HTML][HTML] “No-reflow” phenomenon: A contemporary review
Primary percutaneous angioplasty (pPCI), represents the reperfusion strategy of choice for
patients with STEMI according to current international guidelines of the European Society of …
patients with STEMI according to current international guidelines of the European Society of …
Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction
M Galli, G Niccoli, G De Maria, S Brugaletta… - Nature Reviews …, 2024 - nature.com
Despite prompt epicardial recanalization in patients presenting with ST-segment elevation
myocardial infarction (STEMI), coronary microvascular obstruction and dysfunction (CMVO) …
myocardial infarction (STEMI), coronary microvascular obstruction and dysfunction (CMVO) …
State of the art: no-reflow phenomenon
G Caiazzo, RL Musci, L Frediani… - Cardiology …, 2020 - cardiology.theclinics.com
The occurrence of the no-reflow phenomenon still represents an important clinical issue
during pPCI and can negate the benefits of restoring culprit-vessel patency. Novel promising …
during pPCI and can negate the benefits of restoring culprit-vessel patency. Novel promising …
[HTML][HTML] Coronary No-Reflow after Primary Percutaneous Coronary Intervention—Current Knowledge on Pathophysiology, Diagnosis, Clinical Impact and Therapy
G Ndrepepa, A Kastrati - Journal of Clinical Medicine, 2023 - mdpi.com
Coronary no-reflow (CNR) is a frequent phenomenon that develops in patients with ST-
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …
segment elevation myocardial infarction (STEMI) following reperfusion therapy. CNR is …
Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study
A Darwish, AF Frere, M Abdelsamie… - Annals of Saudi …, 2022 - annsaudimed.net
BACKGROUND: The no-reflow phenomenon is associated with a considerable reduction in
myocardial salvage in patients with ST elevation myocardial infarction (STEMI) treated by …
myocardial salvage in patients with ST elevation myocardial infarction (STEMI) treated by …
Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review …
E Jafari Afshar, P Samimisedeh… - Therapeutic …, 2023 - journals.sagepub.com
Background: Currently, no pharmacological or device-based intervention has been fully
proven to reverse the no-reflow phenomenon. Objectives: To assess the efficacy and safety …
proven to reverse the no-reflow phenomenon. Objectives: To assess the efficacy and safety …
[HTML][HTML] Microvascular Obstruction in Acute Myocardial Infarction, a Potential Therapeutic Target
M Ghobrial, B Bawamia, T Cartlidge… - Journal of Clinical …, 2023 - mdpi.com
Microvascular obstruction (MVO) is a recognised phenomenon following mechanical
reperfusion in patients presenting with ST-segment elevation myocardial infarction (STEMI) …
reperfusion in patients presenting with ST-segment elevation myocardial infarction (STEMI) …
[HTML][HTML] A historical literature review of coronary microvascular obstruction and intra-myocardial hemorrhage as functional/structural phenomena
LN Maslov, NV Naryzhnaya, SV Popov… - Journal of Biomedical …, 2023 - ncbi.nlm.nih.gov
The analysis of experimental data demonstrates that platelets and neutrophils are involved
in the no-reflow phenomenon, also known as microvascular obstruction (MVO). However …
in the no-reflow phenomenon, also known as microvascular obstruction (MVO). However …
Efficiency and Safety of Intracoronary Epinephrine Administration in Patients With ST-Elevation Myocardial Infarction With Refractory Coronary No-Reflow
V Ryabov, S Dil, E Vyshlov, O Mochula… - The American Journal of …, 2024 - Elsevier
Studies assessing the treatment of refractory no-reflow in patients with ST-elevation
myocardial infarction (STEMI) are limited to clinical cases and pilot studies. This study aimed …
myocardial infarction (STEMI) are limited to clinical cases and pilot studies. This study aimed …
[HTML][HTML] PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
A prasad Bodapati, A Hanif, DK Okafor, G Katyal… - Cureus, 2023 - ncbi.nlm.nih.gov
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been approved to treat
dyslipidaemia. However, there is a lack of knowledge on the most efficient PCSK9 therapies …
dyslipidaemia. However, there is a lack of knowledge on the most efficient PCSK9 therapies …